H.C. Wainwright analyst Oren Livnat reiterated a Buy rating and $12.50 price target on Trevi Therapeutics (NASDAQ: TRVI).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE